Webinar

How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies? Should companies adjust their agency communication strategies...

Join Dr. Marco Davila to explore a novel anti-CD83 CAR-T design for relapsed/refractory AML that overcomes myelosuppression barriers. Register for the live session. Developing effective Chimeric Antigen Receptor (CAR) T-cell...